---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-060879"
form_type: "8-K"
ticker: "PFSA"
cik: "0001859807"
company_name: "Profusa, Inc."
filed_at: "2026-05-26T15:05:14+00:00"
generated_at: "2026-05-26T15:07:00.627884+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Profusa and Bio Insights amend asset purchase agreement; delete provision for 12% management share issuance

## Summary
- Amendment removes Section 4.6 requiring issuance of 12% fully diluted shares to CEO and CFO as retention.
- $30M purchase price for PanOmics multi-omics assay know-how, paid in Series A Convertible Preferred, unchanged.
- Amendment confirms no other changes to the Asset Purchase Agreement remain in full force.

## SEC filing metadata
- accession: 0001213900-26-060879
- form_type: 8-K
- ticker: PFSA
- cik: 0001859807
- company_name: Profusa, Inc.
- filed_at: 2026-05-26T15:05:14+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859807/000121390026060879/0001213900-26-060879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859807/000121390026060879/ea0292151-8k_profusa.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-060879
- JSON: https://secwatch.observer/filing/0001213900-26-060879.json
- Plain text: https://secwatch.observer/filing/0001213900-26-060879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.